A Long-term Observational Study in Participants Who Have Received PBGENE-HBV

A Long-term Observational Study in Participants Who Have Received PBGENE-HBV, an In Vivo Gene Editing Investigational Product, in a Prior Clinical Study

Status

Enrolling by invitation

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07254208

Acronym

ELIMINATE-B

Enrollment

Registered

2025-11-28

Start date

2025-12-25

Completion date

2040-06-01

Last updated

2026-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic HBV Infection

Keywords

Hepatitis B Chronic, Gene Therapy, Gene Editing, PBGENE-HBV

Brief summary

Participants who received at least one dose of PBGENE-HBV will be enrolled in this LTFU study.

Detailed description

This is a LTFU observational study designed to evaluate the safety of PBGENE-HBV in participants previously exposed to PBGENE-HBV. This study protocol does not include administration of PBGENE-HBV.

Interventions

BIOLOGICALPBGENE-HBV

PBGENE-HBV is the investigational product administered in the parent study. This LTFU study is non-interventional; no investigational product given.

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to 80 Years

Healthy volunteers

Inclusion criteria

1. Participant has received at least 1 dose of PBGENE-HBV investigational product in a prior clinical study 2. Participant, or their legally authorized representative, has provided signed informed consent.

Exclusion criteria

* N/A

Design outcomes

Primary

Measure	Time frame	Description
Safety to assess frequency, severity, and outcome of delayed adverse events	15 years	Delayed adverse events

Countries

Hong Kong, Moldova, New Zealand, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 23, 2026